GLOW Stack (GHK-Cu + TB-500 + BPC-157) vs Wolverine Stack (BPC-157 + TB-500)

GLOW Stack (GHK-Cu + TB-500 + BPC-157)

This product is a blend of three research peptides, GHK-Cu, TB-500 and BPC-157, supplied together in a single preparation. GHK-Cu is the copper(II) complex of the tripeptide glycyl-histidyl-lysine, first isolated from human plasma. TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ, copied from the actin-binding region of thymosin β4. BPC-157 is a synthetic 15-residue peptide whose sequence was taken from a protein described in gastric juice. Each has its own literature, mostly in cell culture and animal models, but no published study has tested the three together, and there are no data on their stability or behaviour as a mixture.

Wolverine Stack (BPC-157 + TB-500)

This blend combines two synthetic peptides, BPC-157 and TB-500, supplied together as one product; it is not a new compound. BPC-157 is a 15-residue peptide whose sequence its originators describe as derived from a protein in gastric juice; almost all of its literature comes from rodent studies, much of it from a single research group, and human data are very limited. TB-500 is the synthetic seven-residue fragment Ac-LKKTETQ of thymosin β4, and most related research concerns the full-length 43-residue protein rather than the fragment. We are not aware of any published study that has tested the two peptides together, so the blend has no literature of its own.

How GLOW Stack (GHK-Cu + TB-500 + BPC-157) acts

No mechanism has been described for the blend itself, so only the components can be discussed, each on its own evidence. GHK binds copper(II) with high affinity, and the complex has been examined in fibroblast cultures for changes in collagen and glycosaminoglycan synthesis. Thymosin β4 binds monomeric actin and regulates how much is available for filament assembly; TB-500 copies LKKTETQ, the short sequence at the centre of that binding region, and how far the fragment shares the binding is not well established. The mode of action of BPC-157 is unsettled, with rodent and cell studies examining nitric oxide signalling and VEGF receptor pathways. Whether the three interact with one another has not been investigated.

How Wolverine Stack (BPC-157 + TB-500) acts

The two components are reported to act through different pathways, and no interaction between them has been studied. BPC-157 has no identified receptor; rodent and cell studies have linked it to nitric oxide signalling, to the VEGFR2 pathway in endothelial cells and to focal adhesion kinase and paxillin in cultured tendon fibroblasts. TB-500 reproduces the central actin-binding motif of thymosin β4, which in the full-length protein binds monomeric G-actin and regulates the pool of unpolymerised actin; how far the short fragment shares that binding is not well established.

The records side by side

• Type: GLOW Stack (GHK-Cu + TB-500 + BPC-157), Three-peptide blend; Wolverine Stack (BPC-157 + TB-500), Two-peptide blend

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.